Search results
Showing 1351 to 1365 of 1560 results for do not do recommendations
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (HTG400)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi.
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.
MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)
NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)
Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.
Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
View recommendations for TA380Show all sections
Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
XprESS multi sinus dilation system for treating chronic sinusitis (HTG424)
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed.
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .
Macimorelin for diagnosing growth hormone deficiency (MIB320)
NICE has developed a medtech innovation briefing (MIB) on macimorelin for diagnosing growth hormone deficiency .